If you are looking for guidance based on this study's results:
Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI IFM_05-May 2022
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. If you are looking for guidance based on
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. The study demonstrated a clear overall survival benefit
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations
